Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol–remifentanil anesthesia

详细信息    查看全文

• 作者：Takahiro Moriyama ; Akira Matsunaga ; Osamu Nagata ; Kei Enohata…
• 关键词：Rocuronium ; Continuous administration ; Total intravenous anesthesia ; Effect ; site concentration
• 刊名：Journal of Anesthesia
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：29
• 期：4
• 页码：593-599
• 全文大小：681 KB
• 参考文献：1.Wierda JM, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth. 1991;38:430-.CrossRef PubMed
  2.Miller DR, Wherrett C, Hull K, Watson J, Legault S. Cumulation characteristics of cisatracurium and rocuronium during continuous infusion. Can J Anaesth. 2000;47:943-.CrossRef PubMed
  3.Sparr HJ, Wierda JM, Proost JH, Keller C, Khuenl-Brady KS. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. Br J Anaesth. 1997;78:267-3.CrossRef PubMed
  4.Shanks CA, Fragen RJ, Ling D. Continuous intravenous infusion of rocuronium (ORG 9426) in patients receiving balanced, enflurane, or isoflurane anesthesia. Anesthesiology. 1993;78:649-1.CrossRef PubMed
  5.McCoy EP, Mirakhur RK, Maddineni VR, Wierda JM, Proost JH. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth. 1996;76:29-3.CrossRef PubMed
  6.Xue FS, Tong SY, Liao X, Liu JH, An G, Luo LK. Dose-response and time course of effect of rocuronium in male and female. Anesth Analg. 1997;85:667-1.PubMed
  7.Bevan DR, Fiset P, Balendran P, Law-Min JC, Ratcliffe A, Donati F. Pharmacodynamic behavior of rocuronium in the elderly. Can J Anaesth. 1993;40:127-2.CrossRef PubMed
  8.Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamics effects of rocuronium when dosed according to real body weight or ideal body weight in mobidly obese patients. Anesth Analg. 2004;99:1086-.CrossRef PubMed
  9.Meyhoff CS, Lund J, Jenstrup MT, Claudius C, Sorensen AM, Viby-Mogensen J, Rasmussen LS. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg. 2009;109:787-2.CrossRef PubMed
  10.Dahaba AA, Perelman SI, Moskowitz DM, Bennett HL, Shander A, Xiao Z, Huang L, An G, Bornemann H, Wilfinger G, Hager B, Rehak PH, List WF, Metzler H. Geographic regional differences in rocuronium bromide dose-response relation and time course of action: an overlooked factor in determining recommended dosage. Anesthesiology. 2006;104:950-.CrossRef PubMed
  11.Fuchs-Buder T, Claudis C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Monngensen J. 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamics studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789-08.CrossRef PubMed
  12.Valadares de Moraes N, Rocha Lauretti G, Campos de Filgueira G, Carvalho Portes Lopes B, Lanchote VL. Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. J Pharm Biomed Anal. 2014; 90:180-.
  13.Kotake Y, Takeda J, Ozaki M, Saeki S, Otagiri T, Kiyama S, Uchimoto R, Iwao Y. Randamized, multicenter study of interaction between Org 9426 (rocuronium bromide) and anesthestic agents in Japanese population (in Japanese with English abstract). Masui (Jpn J Anesthesiol). 2006;55:873-.
  14.Bissinger U, Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Physiol Res. 2000;49:455-2.PubMed
  15.Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia. 2001;56:312-.CrossRef PubMed
  16.Kim KS, Lew SH, Cho HY, Cheong MA. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine. Anesth Analg. 2002;95:1656-0.CrossRef PubMed
  17.Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98:1042-.CrossRef PubMed
  18.Cammu G, De Witte J, De Veylder J, Bytebier G, Vandeput D, Foubert L, Vandenbroucke G, Deloof T. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006;102:426-.CrossRef PubMed
  19.Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twich response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg. 2007;104:582-.CrossRef PubMed
  20.Takagi S, Ozaki M, Iwasaki H, Hatano Y, Takeda J. Effects of sevoflurane and propofol on neuromuscular blocking action of Org 9426 (rocuronium bromide) infused continuously in Japanese patients (in Japanese with English abstract). Masui (Jpn J Anesthesiol). 2006;55:963-.
  21.Fujimoto M, Tanahira C, Nishi M, Yamamoto T. In non-obese patients, duration of action of rocuronium is directly correlated with body mass index. Can J Anaesth. 2013;60:552-.CrossRef PubMed
  22.Olkkola KT, Tammisto T. Quantifying the interaction of rocuronium (Org 9426) with etomidate, fentanyl, midazolam, propofol, thiopental, and is
• 作者单位：Takahiro Moriyama (1)
  Akira Matsunaga (1)
  Osamu Nagata (1)
  Kei Enohata (1)
  Tomomi Kamikawaji (1)
  Erika Uchino (1)
  Yuichi Kanmura (1)
  
  1. Department of Anesthesiology and Intensive Care, Kagoshima University Hospital, Sakuragaoka 8-35-1, Kagoshima, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Anesthesiology
  
• 出版者：Springer Japan
• ISSN：1438-8359

文摘

Background Rocuronium bromide (Rb) is a rapid onset, intermediate-acting neuromuscular blocking agent that is suitable for continuous administration. The appropriate rate of rocuronium administration is, however, difficult to determine due to large interindividual differences in sensitivity to rocuronium. The aim of this study was to clarify whether the simulated rocuronium concentration at the time of recovery to %T1 > 0 % after the initial administration of rocuronium is a good indicator of optimal effect-site concentrations during continuous rocuronium administration.